Real World Study of Four PD-1 Agents in China

Qingdao University

Status: Unknown

Conditions: Malignant Melanoma; Abdomen Tumors; Gynecologic Cancer; Thoracic Cancer

Treatments: Drug: Chemotherapy

Study type: Observational

Funder types: Other

Identifiers

NCT03966456

Ic-01

Details and patient eligibility

About

Consecutive patients treated with PD-1 therapy in Qingdao City were included in our study. The effecy and safety of the four PD-1 agents according to clinical outcomes in real world will be studied.

Full description

Consecutive patients treated with PD-1 therapy in Qingdao City were included in our study. The effecy and safety of the four PD-1 agents according to clinical outcomes in real world will be studied. ORR will be studied of the four PD-1 agents（nivolumab, pembrolizumab, toripalimab, sintilimab）

Enrollment: 500 estimated patients

Sex: All

Ages: 18 to 90 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients with lung cancer, liver cancer and other solid cancers
• Histologically or cytologically confirmed diagnosis cancer treated with PD-1 agents
• At least one measurable lesion
• Eastern Cooperative Oncology Group (ECOG) Performance Scale 0 or 1 Adequate organ function

Exclusion criteria

• patients treated with PD-1 agents less than 2 terms

Trial design

500 participants in 4 patient groups

nivolumab

Description:

Consecutive patients treated with nivolumab single or combined chemotherapy/targeting therapy.

Treatment:

Drug: Chemotherapy

pembrolizumab

Description:

Consecutive patients treated with pembrolizumab single or combined chemotherapy/targeting therapy.

Treatment:

Drug: Chemotherapy

toripalimab

Description:

Consecutive patients treated with toripalimab single or combined chemotherapy/targeting therapy.

Treatment:

Drug: Chemotherapy

sintilimab

Description:

Consecutive patients treated with sintilimab single or combined chemotherapy/targeting therapy.

Treatment:

Drug: Chemotherapy